UNITED STATES SECURITIES AND EXCHANGE ~~COMMISSIONWashington, D.C. 20549~~COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF ~~UNDER~~ THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~February~~ March 2019

Commission File Number: ~~333~~001-~~219066~~38177

Clementia Pharmaceuticals Inc.~~(Translation of registrant's name into English)~~

~~1000 de la Gauchetiere Street West, Suite 1200 Montreal, Quebec, CANADA , H3B 4W5~~(~~Address~~Translation of ~~principal~~registrant’s name ~~executive~~into ~~office~~English)

~~Indicate~~4150 bySainte-Catherine ~~check~~Street ~~mark~~West, Suite ~~whether~~550 Montreal, ~~the~~Quebec, ~~registrant~~Canada ~~files~~H3Z or2Y5 (Address ~~will file annual reports under cover~~ of ~~Form~~principal ~~20-F~~executive ~~or Form 40-F. Form 20-F [ X ] Form 40-F [ ]~~office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

~~Note:~~DOCUMENTS ~~Regulation~~FURNISHED ~~S-T~~AS ~~Rule~~PART ~~101(b)(7)~~OF ~~only~~THIS ~~permits the submission in paper of a Form~~ FORM 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

~~The~~A ~~information~~press ~~contained~~release indated ~~this~~March ~~Report~~6, ~~(including the exhibits hereto) is hereby incorporated by reference into Clementia Pharmaceuticals Inc~~2019.~~’s Registration Statement on Form F-3 (File No. 333-227726).~~

OnSupport ~~February~~and 28Voting Agreement dated March 2, 2019, ~~the~~between ~~Registrant~~BDC ~~provided~~Capital aInc., ~~Notice~~11188291 ofCanada ~~its Annual General Meeting which is attached hereto as Exhibit 99~~Inc.1 and isIpsen ~~incorporated herein by reference~~S.A.

~~(c)~~Support ~~Exhibit~~and ~~99.1.~~Voting ~~Notice~~Agreement ofdated ~~Annual~~March 4, ~~General~~2019, ~~Meeting~~between ~~dated~~New ~~February~~Enterprise 28Associates 15, ~~2019~~L.P., 11188291 Canada Inc. and Ipsen S.A.

Exhibits

99.1 – Press Release dated March 6, 2019

99.2 – Support and Voting Agreement dated March 2, 2019, between BDC Capital Inc., 11188291 Canada Inc. and Ipsen S.A.

99.3 – Support and Voting Agreement dated March 4, 2019, between New Enterprise Associates 15, L.P., 11188291 Canada Inc. and Ipsen S.A.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clementia Pharmaceuticals Inc.
	(Registrant)
Date: February 28, 2019
Date: March 6, 2019	By:	/s/ Clarissa Desjardins
	/s/ Steve Forte
		Clarissa Desjardins
	Steve Forte
		Chief Executive Officer
	Chief Financial Officer

Filing Compare · Clementia Pharmaceuticals Inc.